Comparative Pharmacology
Head-to-head clinical analysis: KRINTAFEL versus QUININE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KRINTAFEL versus QUININE SULFATE.
KRINTAFEL vs QUININE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
Quinine sulfate is a blood schizonticide effective against the asexual erythrocytic forms of Plasmodium spp. It interferes with the parasite's ability to digest hemoglobin, leading to accumulation of toxic heme and parasite death. Quinine also has mild analgesic and antipyretic effects, and may depress cardiac conduction and contractility.
Adults: 200 mg orally as a single dose.
324 mg orally every 8 hours for 7 days (for treatment of chloroquine-resistant falciparum malaria, in combination with other antimalarials).
None Documented
None Documented
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Terminal elimination half-life: 18 hours (range 16-21 hours) in healthy adults; prolonged in renal impairment (up to 25-30 hours) and severe hepatic impairment.
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Renal: 20% unchanged; hepatic metabolism (CYP3A4, CYP2C9) accounts for 80% with metabolites (primarily 3-hydroxyquinine) excreted renally and fecally. Biliary excretion is minor (<5%).
Category C
Category D/X
Antimalarial
Antimalarial